Treatment of low-risk ductal carcinoma in situ: is nothing better than something?

The Lancet Oncology

Volumn 17, Issue 10, 2016, Pages e442-e451

  Benson, John R ^a   Jatoi, Ismail ^b   Toi, Masakazu ^c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; BREAST RECONSTRUCTION; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR BIOPSY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY CANCER DIAGNOSIS; ETIOLOGY; FEMALE; MORTALITY; PATHOLOGY; RISK; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EARLY DETECTION OF CANCER; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK;

EID: 84992397146     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30367-9     Document Type: Review

References (73)

1. 1 Rosen, PP, Braun, DW, Kinne, DE, The clinical significance of pre-invasive breast cancer. Cancer 46 (1980), 919–925.
2. 2 Pinder, SE, Duggan, C, Ellis, IO, et al. A new pathological system for grading DCIS with improved prediction of local recurrence results from the UKCCCR/ANZ DCIS trial. Br J Cancer 103 (2010), 94–100.
3. 3 Benson, JR, Wishart, GC, Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol 14 (2013), e348–e357.
4. 4 Rea, D, New UK DCIS trial aims to help women avoid unnecessary breast operations. www.totalhealth.co.uk/.../new-uk-dcis-trial-aims-help-women-avoid-unnecessary-breast-operations (accessed Sept 1, 2016).
5. 5 Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380 (2012), 1778–1786.
6. 6 Francis, A, Thomas, J, Fallowfield, L, et al. Addressing overtreatment of screen-detected DCIS; the LORIS trial. Eur J Cancer 51 (2015), 2296–2302.
7. 7 Narod, S, Iqbal, J, Giannakeas, V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1 (2015), 888–896.
8. 8 Pinder, S, Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol 23 (2010), S8–13.
9. 9 Jeevan, R, Cromwell, D, Brown, J, National mastectomy and breast reconstruction audit 2011, 2011, the NHS Information Centre, Leeds.
10. 10 Skaane, P, Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: an updated review. Acta Radiol 50 (2009), 3–14.
11. 11 Cancer Research, UK, In situ breast carcinoma incidence statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-in-situ (accessed Sept 19, 2016).
12. 12 American Cancer Society. American Cancer Society breast cancer facts and figures 2011. www.cancer.org/research/cancerfactsstatistics/acspc-046381 (accessed Sept 1, 2016).
13. 13 Bleyer, A, Welch, HG, Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med 367 (2012), 1998–2005.
14. 14 Welch, HG, Black, WC, Using autopsy series to estimate the disease ‘reservoir’ for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med 127 (1997), 1023–1028.
15. 15 Benson, JR, The biological basis for breast cancer screening. Benson, JR, Gui, G, Tuttle, T, (eds.) Early breast cancer: from screening to multidisciplinary management, 3rd edn., 2013, CRC Press, Boca Raton, FL, 50–67.
16. 16 Benson, JR, Will ductal carcinoma in situ defeat breast cancer screening?. BMJ, 338, 2009, 615.
17. 17 Kerlikowski, K, Salzman, P, Philips, KA, et al. Continuing screening mammography in women aged 70–79 years: impact on life expectancy and cost-effectiveness. JAMA 282 (1999), 2156–2163.
18. 18 Gøtzsche, PC, Olsen, O, Is screening for breast cancer with mammography justifiable?. Lancet 355 (2000), 129–134.
19. 19 Worni, M, Akushevich, I, Greenys, R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ (DCIS). J Natl Cancer Inst, 107, 2015, djv263.
20. 20 Jatoi, I, Anderson, WE, Cancer screening. Curr Prob Surg 42 (2005), 620–682.
21. 21 Jatoi, I, The impact of advances in treatment on the efficacy of mammography screening. Prev Med 53 (2011), 103–104.
22. 22 Worni, M, Akushevich, I, Greenup, R, et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J Natl Cancer Inst, 107, 2015, djv263.
23. 23 Altman, LK, Surgeons remove cancerous breast of Nancy Reagan. http://www.nytimes.com/1987/10/18/us/surgeons-remove-cancerous-breast-of-nancy-reagan.html?pagewanted=all (accessed May 30, 2016).
24. 24 Elshof, LE, Tryfonidis, K, Slaets, L, et al. Feasibility of a prospective, randomized, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer 51 (2015), 1497–1510.
25. 25 Gotzsche, PC, Jorgensen, KJ, Screening for breast cancer with mammography. Cochrane Database Syst Rev, 6, 2013 CD001877.
26. 26 Tabár, L, Gad, A, Holmberg, LH, et al. Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the Breast Cancer Screening Working Group of the Swedish Board of Health and Welfare. Lancet 325 (1985), 829–832.
27. 27 Shapiro, S, Venet, W, Strax, P, Venet, L, Periodic screening for breast cancer. In: The Health Insurance Plan Project and its sequelae, 1963–1986, 1988, Johns Hopkins University Press, Baltimore.
28. 28 Andersson, I, Aspegren, K, Janzon, L, et al. Mammographic screening and mortality froom breast cancer: the Malmo mammographic screening trial. BMJ 297 (1988), 943–948.
29. 29 Gotzsche, P, Nielsen, M, Screening for breast cancer with mammography. Cochrane Database Syst Rev, 4, 2009 CD001877.
30. 30 Miller, AB, Wall, C, Baines, CJ, et al. Twenty five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ, 348, 2014, g366.
31. 31 Tabár, L, Re: twenty five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial (letter). BMJ, 348, 2014, g366.
32. 32 Kerlikowski, K, Grady, D, Rubin, SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 273 (1995), 149–154.
33. 33 Welch HG. Screening and overdiagnosis. 36th San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 10–14, 2013.
34. 34 Thornton, H, Communicating the benefits, harms and risks of medical interventions. J Epidemiol Public Health 64 (2010), 101–102.
35. 35 Baum, M, McCartney, M, Thornton, H, et al. Breast cancer screening peril. Negative consequences of the breast screening programme. www.dcscience.net/Times-breast-cancer%20screening-190209.pdf (accessed Sept 1, 2016).
36. 36 National Health Service Information Centre. Breast screening programme, England 2009–10. digital.nhs.uk/catalogue/PUB01051/brea-scre-prog-eng-2009-2010-rep.pdf (accessed June 4, 2016).
37. 37 Elmore, JG, Nakano, CY, Koepsell, TD, et al. International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 95 (2003), 1384–1393.
38. 38 Peeters, PHM, Verbeek, ALM, Straatman, H, et al. Evaluation of overdiagnosis of breast cancer in screening with mammography; results of the Nijmegen programme. Int J Epidemiol 18 (1989), 295–299.
39. 39 Fisher, B, Costantino, J, Redmond, C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328 (1993), 1581–1586.
40. 40 Fisher, B, Dignam, J, Wolmark, N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999), 1993–2000.
41. 41 Holland, R, Peterse, JL, Millis, R, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11 (1994), 167–180.
42. 42 Lagios, MD, Margolin, FR, Westdahl, PR, et al. Mammographically detected ductal carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63 (1989), 618–624.
43. 43 Julien, JP, Bijker, N, Fentiman, IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355 (2000), 528–533.
44. 44 Emdin, SO, Granstrand, B, Ringberg, A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomized trial in a population offered mammographic screening. Acta Oncol 45 (2006), 536–543.
45. 45 Early Breast Cancer Trialists Collaborative Group. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst 41 (2010), 162–177.
46. 46 Houghton, J, George, WD, Cuzick, J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized controlled trial. Lancet 362 (2003), 95–102.
47. 47 Carlson, RW, Berry, DA, Burstein, HJ, et al. NCCN clinical practice guidelines in oncology: breast cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp (accessed Sept 16, 2016).
48. 48 National Institute for Health and Care Excellence. Breast cancer (early and locally advanced): diagnosis and treatment. https://www.nice.org.uk/guidance/cg80?unlid=506387327201511247422 (accessed Sept 1, 2016).
49. 49 Solin, L, Gray, R, Hughes, LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33 (2015), 3938–3944.
50. 50 McCormick, B, Winter, K, Hudis, C, et al. RTOG 9804: a prospective randomized trial for good risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33 (2015), 709–715.
51. 51 Bath, C, Expect questions about treatment for ductal carcinoma in situ. ASCO Post, Oct 10 2015 https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp (accessed Sept 16, 2016).
52. 52 Kramer, BS, Croswell, JM, Cancer screening: the clash of science and intuition. Annu Rev Med 60 (2009), 125–137.
53. 53 Esserman, L, Yau, C, Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1 (2015), 888–896.
54. 54 Lagios, MD, Margolin, FR, Westdahl, PR, et al. Mammographically detected ductal carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63 (1989), 616–624.
55. 55 Page, D, Steel, CM, Dixon, JM, et al. Carcinoma in situ and patients at high risk of breast cancer. BMJ 310 (1995), 39–42.
56. 56 Sanders, ME, Schuyler, PA, Dupont, WD, Page, DL, The natural history of low grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long term follow up. Cancer 103 (2005), 2481–2484.
57. 57 Collins, LC, Tamimi, RM, Baer, HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 103 (2005), 1778–1784.
58. 58 Lopez-Garcia, MA, Geyer, FC, Lacroix-Triki, M, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 57 (2010), 171–192.
59. 59 Hernandez, L, Wilkerson, PM, Lambros, MB, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol 227 (2012), 42–52.
60. 60 Bijker, N, Peterse, H, Duchateau, L, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma-in-situ. Br J Cancer 84 (2001), 539–544.
61. 61 Millis, RR, Barnes, DM, Lampejo, OT, et al. Tumour grade does not change between primary and recurrent mammary carcinoma. Eur J Cancer 34 (1998), 548–553.
62. 62 Bombanati, A, Sgroi, DC, The molecular pathology of breast cancer progression. J Pathol 223 (2011), 307–317.
63. 63 Wallis, MG, Clements, K, Kearins, O, et al. The effect of DCIS grade on rate, type and time of recurrence after 15 years of follow up of screen-detected DCIS. Br J Cancer 106 (2012), 1611–1617.
64. 64 Soumjan, S, Verghese, ER, Booth, M, et al. Concordance between vacuum-assisted biopsy and postoperative histology: implications for the proposed Low Risk DCIS Trial (LORIS). Eur J Surg Oncol 39 (2013), 1337–1340.
65. 65 Keurer, H, Ductal carcinoma in situ: treatment or active surveillance?. Expert Rev Anticancer Ther 15 (2015), 777–785.
66. 66 Morrow, M, Katz, SJ, Addressing overtreatment in DCIS: what should physicians do?. J Natl Cancer Inst, 107, 2015, djv290.
67. 67 Schuetz, CS, Bonin, M, Clare, SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66 (2006), 5278–5286.
68. 68 Kerlilowske, K, Moliaro, AM, Gauthier, ML, et al. Biomarker expression and risk of subsequent tumours after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102 (2010), 627–637.
69. 69 Williams, KE, Barnes, NL, Cramer, A, et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 26 (2015), 1019–1025.
70. 70 Solin, L, Gray, R, Baehner, F, et al. A multi-gene expression assay to predict local recurrence risk for ductal carcinoma-in-situ of the breast. J Natl Cancer Inst 105 (2013), 701–710.
71. 71 Rakovitch, E, Nofech-Mozes, S, Hanna, W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast conserving surgery alone. Breast Cancer Res Treat 152 (2015), 389–398.
72. 72 Brennan, ME, Turner, RM, Ciatto, S, et al. Ductal carcinoma in situ at core needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260 (2011), 119–128.
73. 73 Pilewskie, M, Olcese, C, Patil, S, et al. Long-term rates of ipsilateral breast tumour recurrence (IBTR) for women with ductal carcinoma in situ (DCIS) meeting LORIS trial eligibility criteria undergoing standard therapy. J Clin Oncol, 33(suppl), 2015 abstr 560.